Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02908633
Other study ID # 76/WIM/2015
Secondary ID 76/WIM/015
Status Recruiting
Phase N/A
First received September 17, 2016
Last updated September 17, 2016
Start date February 2016
Est. completion date December 2019

Study information

Verified date September 2016
Source Military Institute of Medicine, Poland
Contact Marek Rekas, MD, PhD , Professor
Phone +48604113659
Email rekaspl@gmail.com
Is FDA regulated No
Health authority Poland: MMI Ethics committee
Study type Interventional

Clinical Trial Summary

It is a comparative study of Safety and Efficacy of Three Variants of Canaloplasty: ab-externo, ab-interno and minicanaloplasty. Combined With Phacoemulsification to Treat Glaucoma and Cataract. It is a Randomised, Prospective Study.


Recruitment information / eligibility

Status Recruiting
Enrollment 90
Est. completion date December 2019
Est. primary completion date December 2018
Accepts healthy volunteers No
Gender Both
Age group 21 Years and older
Eligibility Inclusion Criteria:

- co-existing glaucoma and cataract

- glaucoma types: primary open angle glaucoma,

- eye with characteristic glaucoma changes (biomicroscopic,visual field)

- IOP over 21 mmHg after washout

- patients not tolerating antiglaucoma medications,

- patients with poor compliance

- progression in visual field

Exclusion Criteria:

- previous surgical glaucoma procedure

- previous cataract surgery

- BCVA under 0,004

- closed angle glaucoma secondary glaucoma (pseudoexfoliative, pigmentary)

- poorly controlled diabetes mellitus

- advanced AMD

- active inflammatory disease

- pregnancy

- mental disease or emotional instability general steroid therapy

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Procedure:
canaloplasty and phacoemulsification


Locations

Country Name City State
Poland Military Institute of Medicine Warsaw

Sponsors (1)

Lead Sponsor Collaborator
Military Institute of Medicine, Poland

Country where clinical trial is conducted

Poland, 

Outcome

Type Measure Description Time frame Safety issue
Primary mean IOP change form baseline at 24 months No
Primary Number of antiglaucoma drugs change from baseline at 24 months No
Primary intraoperative complications at the day of surgery No
Secondary Best-Corrected Visual Acuity change from baseline at 24 months No
Secondary Visual Field changes MD, change from baseline at 24 months No
Secondary Early and Late postsurgical complications within 24 months No
Secondary % IOP reduction change at 24 months from baseline No